U.S. Measurement System



Imaging as a Biomarker: Standards for Change Measurements in Therapy

Breakout Area 6: Data Archival & Access Methods: Image, Related Meta-data and Clinical Outcome Data, Related Data Interoperability Standards, and Innovative Methodologies for Data Interpretation

Day 1: Summary of "Big Picture Roadmapping – The What by When?"

Near, Mid and Long-Term Issues

Chair, Michael Vannier, MD
Department of Radiology
University of Chicago

A U.S. Measurement System Workshop September 14-15, 2006 National Institute of Standards and Technology

Breakout Area 6: Data Archival & Access Methods Near-Term 1-3 Years

1.	State	Innovation or Challenge: 21CFR11 compliant image
	uatab	ase with audit trail (e.g., RT objects)
		Impact of Success: FDA will accept; can meet regulatory requirements
		Technical Barriers: DICOM doesn't have audit trail; unwelcome burden for PACS system; content management
		Key Players: DICOM, pharma, CRO
2.		Innovation or Challenge: Need research PACS, but most clinical PACS
		Impact of Success: Enables and facilitates clinical trial use of images
		Technical Barriers: PACS systems are closed; vendors are not motivated to provide flexible integration of clinical trials data
		Key Players: PACS, RIS and HIS developers; PACS customers
3.	State	Innovation or Challenge: Legacy PACS = huge installed
	base,	not suitable for research (has some, but not all necessary
		workflow is not optimal for clinical research)
		Impact of Success: Allows innovative use of images; clinical trials
		Technical Barriers: Economics unfavorable; benefits difficult to quantify; add-on or add-in
		Key Players: PACS vendors; clinical trialists, healthcare IT

Breakout Area 6: Data Archival & Access Methods

Near-Term 1-3 Years

4.		Innovation or Challenge: DICOM and ISO 11179 metadata; C integration of images
		Impact of Success: Use generic tools to handle image + other biomedical data
		Technical Barriers: caBIG is ISO 11179 compliant, but cancer is pathology driven
		Key Players: DICOM, NCI, CRO; CDISC
5.	State	Innovation or Challenge: Capture image-guided treatment plans
		Impact of Success: reuse plans; quality control across centers (e.g., rf ablation)
		Technical Barriers: target and day-to-day changes in morphology not defined; borrow on experience of ATC
		Key Players: DICOM, ATC, NCI, interventional companies and radiologists
6.	State	Innovation or Challenge: PET, MRI, neuropsych, genetic data
	over	time on same individuals; Establish imaging as a surrogate markei
	for cl	inical outcomes
		Impact of Success: Validation of imaging biomarkers
		Technical Barriers: Need to integrate multitemporal datasets on individuals linked to outcomes
		Key Players: ADNI; OAI; RIDER

Breakout Area 6: Data Archival & Access Methods Short-Term 1-3 Years

- 7. State Innovation or Challenge: Discovery database; data mining of human clinical trial image collections; enterprise archive
 - Impact of Success: better ability for drug development
 - ☐ Technical Barriers: incompatible data in local, private databases; proprietary code in tools;
 - Key Players: pharma, CRO, clinical sites; IT vendors

Breakout Area 6: Data Archival & Access Methods Mid-Term 3-5 Years

1.	State Innovation or Challenge: Know effects of oncology treatment over time and link to outcomes; flexible ability to add modalities and ancillary data Impact of Success: Able to sort out treatment effects from		
		other sources of variation	
		Technical Barriers: Difficult to integrate new datasets, modality	
		Key Players: NCI, Rad Onc, Oncologists, Radiology, FDA	
2.	State Innovation or Challenge: Linking disparate data in various systems; Query mechanism for multiple		
	data	bases	
		Impact of Success: allows interoperation of distributed systems, legacy and newer databases	
		Technical Barriers:	
		Key Players: database experts;	

Breakout Area 6: Data Archival & Access Methods Long-Term 5+ Years

1.		e Innovation or Challenge: Integrate images and eptor ligand maps
		Impact of Success: Targeted drug therapies
		Technical Barriers: Multimodality multitemporal data management and analysis
		Key Players: Pharma; SNM – PET; ISMRM;
2.		e Innovation or Challenge: Federated integrated base, like caBIG (has no audit trail) can't be used
	for c	drug regulatory or non-cancer applications
		Impact of Success: Support drug development and reuse of previously collected data
		Technical Barriers: NCI-based initiative of limited value to pharma, limited involvement in design
		Kev Players: NCI, pharma: healthcare IT